Founder and CEO
Max is a scientist who is passionate about technologies for healthcare. He is contributing his knowledge about drug development, biomarkers, and microfluidics to precision medicine.
COO
More than 25 years of translational research, life sciences, cancer biology, laboratory science, regulatory compliance, tech transfer brought to bear in Biotech, Pharma, Biopharma, Medical Device, pre-clinical/clinical trials. Industry, Academia and Government roles. Multiple patents, published scientist and book author, “Bio-engineering of a 3D In Vitro Tumor Model.
CFO
Mark Wesson has experience leading analysis and restructuring of the programs to improve the quality of care for patients. He’s also skilled at cultivating innovation using the latest technologies to improve information management and communication. Over his 20-year career, Mark has designed, conducted, managed, analyzed, or reported many health care projects.
He has disseminated many of the resulting data-driven program proposals and reports directly to providers or senior health care executives. Mark worked with providers, executives, and support staff across the continuum of care within the emergency, inpatient, and outpatient care delivery settings. He simultaneously project managed, coordinated, or consulted on analytic, strategic, financial, operational, or system administration responsibilities.
CSO
Lahiri Nanduri is a biologist with over 15 years of expertise in single-cell methods for oncology. He has lots of publications known as an SME in this field. Lahiri has worked in multiple organizations with organoids, biobanking, and evaluating cutting-edge tools.
Copyright © 2021 FlowCell - All Rights Reserved.